Previous Article | Next Article 
Applied and Environmental Microbiology, April 2000, p. 1572-1579, Vol. 66, No. 4
0099-2240/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Compatible-Solute-Supported Periplasmic Expression
of Functional Recombinant Proteins under Stress Conditions
S.
Barth,1,*
M.
Huhn,1
B.
Matthey,1
A.
Klimka,1
E. A.
Galinski,2 and
A.
Engert1
Department I of Internal Medicine, University
of Cologne, Cologne,1 and Institute of
Biochemistry, University of Münster,
Münster,2 Germany
Received 12 October 1999/Accepted 16 January 2000
 |
ABSTRACT |
The standard method of producing recombinant proteins such as
immunotoxins (rITs) in large quantities is to transform gram-negative bacteria and subsequently recover the desired protein from inclusion bodies by intensive de- and renaturing procedures. The major
disadvantage of this technique is the low yield of active protein. Here
we report the development of a novel strategy for the expression of
functional rIT directed to the periplasmic space of Escherichia coli. rITs were recovered by freeze-thawing of pellets from
shaking cultures of bacteria grown under osmotic stress (4% NaCl plus 0.5 M sorbitol) in the presence of compatible solutes. Compatible solutes, such as glycine betaine and hydroxyectoine, are
low-molecular-weight osmolytes that occur naturally in halophilic
bacteria and are known to protect proteins at high salt concentrations.
Adding 10 mM glycine betaine for the cultivation of E. coli
under osmotic stress not only allowed the bacteria to grow under these
otherwise inhibitory conditions but also produced a periplasmic
microenvironment for the generation of high concentrations of correctly
folded rITs. Protein purified by combinations of metal ion affinity and size exclusion chromatography was substantially stabilized in the
presence of 1 M hydroxyecotine after several rounds of freeze-thawing, even at very low protein concentrations. The binding properties and
cytotoxic potency of the rITs were confirmed by competitive experiments. This novel compatible-solute-guided expression and purification strategy might also be applicable for high-yield periplasmic production of recombinant proteins in different expression systems.
 |
INTRODUCTION |
Recombinant proteins such as
antibodies, recombinant bispecific antibodies (diabodies)
(21), or immunotoxins are increasingly being used to
selectively destroy undesired cells in malignant diseases. Recombinant
immunotoxins are chimeric proteins composed of a truncated,
binding-deficient, catalytically active toxin directly linked to a
recombinant single-chain antibody fragment (scFv) (33).
These fusion gene products are highly homogeneous, much easier to
modify and more economical to produce than chemical conjugates
(29). However, bacterially expressed single-chain immunotoxins vary tremendously in their stability, and some have developed a strong tendency to aggregate (6). The standard method for the isolation and purification of recombinant immunotoxins was developed by Pastan and coworkers (9). Their recombinant immunotoxins were expressed under the control of a T7 late promoter in
transformed Escherichia coli BL21(DE3) and induced after the addition of isopropyl
-D-thiogalactoside (IPTG). The
proteins remained intracellular and appeared to be primarily associated with inclusion bodies (15). Chimeric recombinant protein was purified after careful de- and renaturation procedures by Q-Sepharose, Mono-Q, and size exclusion chromatography on a TSK 250 column (9). Under optimized conditions, only 5 to 10% of the input protein was properly folded and active.
Our group has evaluated the monoclonal antibody (MAb) RFT5, binding to
the interleukin-2 receptor
(CD25), and MAb Ki-4, binding to the
human CD30 receptor, for their potential value in specifically
targeting malignant lymphoma cells (4, 5, 27). In order to
develop an optimized bacterial expression system, we subsequently
constructed pBM1.1, a new pET-based vector for PelB-directed
periplasmic expression of recombinant immunotoxins (31).
Selected RFT5 and Ki-4 scFv's were directionally inserted into this
plasmid and thus genetically fused to a modified Pseudomonas aeruginosa exotoxin A (ETA') gene with a deletion of domain Ia. The problem of production of sufficient amounts of pure and fully active recombinant immunotoxins, however, still remains an obstacle for
clinical application. We therefore used a new strategy for optimized
periplasmic expression under osmotic stress. To cope with these
conditions imposed by saline environments, most halophilic and
halotolerant Bacteria and Eucarya control
cytoplasmic osmolarity by accumulation of a range of organic osmolytes,
referred to as compatible solutes (8, 16). We used
protein-stabilizing compatible solutes (namely, glycerol, sorbitol,
glycine betaine, and hydroxyectoine) during the production phase and/or
in the course of purification and storage to optimize the functionality
and stability of the proteins. To our knowledge, this is the first
study demonstrating highly efficient compatible-solute-assisted
periplasmic production of recombinant chimeric molecules.
 |
MATERIALS AND METHODS |
Bacterial strains, oligonucleotides, and plasmids.
Bacteria
and plasmids used in this study are summarized in Table
1. E. coli XL1-Blue
(Stratagene, Amsterdam, The Netherlands) was used as the host for
cloning and sequencing. E. coli BL21(DE3) (36),
purchased from Novagen (Abingdon, United Kingdom), was used for the
synthesis of recombinant immunotoxins. E. coli TG1 and
E. coli HB2151 (Pharmacia, Freiburg, Germany) were used as hosts for synthesis of scFv-displaying phages and soluble scFv, respectively. Phagemid vector pCANTAB6 (32) was used for
N-terminal fusion of SfiI/NotI-scFv fragments to
the minor coat protein p3 of filamentous phage M13, allowing the
selection of antigen-binding phage (22). Plasmid pBM1.1
(31), derived from the pET27b vector (Novagen), was used for
N-terminal fusion of scFv's to ETA' (39). Synthetic
oligonucleotides were synthesized by Eurogentec (Seraing, Belgium).
Plasmid pcDNA3 (Invitrogen, Groningen, The Netherlands) was used for
eukaryotic expression of recombinant soluble CD30 receptor. Purified
MAb Ki-4 was supplied by Boehringer GmbH (Mannheim, Germany), and
hydroxyectoine was supplied by Bitop GmbH (Witten, Germany). Plasmids
were prepared by the alkaline lysis method and purified using plasmid
kits from Qiagen (Hilden, Germany). Restriction fragments or PCR
products were separated by horizontal agarose gel electrophoresis and
extracted with Qiaex II (Qiagen). Cloning into plasmid vectors was
performed by standard methods (35).
Cell culture.
All cell lines (Table 1), including the
CD25+ CD30+ Hodgkin-derived cell line L540Cy
(25) and the CD25
CD30
Hodgkin-derived cell line HD-MyZ (3) (kindly provided by B. Dörken, Berlin, Germany), as well as the hybridoma cell lines RFT5 (13) and Ki-4 (23) and the simian COS-1
cells, were cultivated in complex medium (RPMI 1640) supplemented with
10% (vol/vol) heat-inactivated fetal calf serum, 50 µg of
penicillin/ml, 100 µg of streptomycin/ml, and 2 mM
L-glutamine. All cells were cultured at 37°C in an
atmosphere of 5% CO2 in air.
Plasmid construction.
Total cellular RNA was isolated from
107 hybridoma cells using RNazol solution (Gibco,
Eggenstein, Germany) as described by the manufacturer. cDNA was
synthesized using 5 µg of freshly prepared RNA and 10 µl of random
hexamer primers (10 µM) from the RiboClone cDNA Synthesis Systems kit
(Promega, Mannheim, Germany) in a 50-µl reaction mixture.
Immunoglobulin variable-region genes (VH and VL) were PCR amplified from 5 µl of cDNA, assembled, and
cloned into pCANTAB6 as described elsewhere (27). Plasmids
were transformed into 50 µl of E. coli TG-1 by
electroporation as described elsewhere (11). Binding RFT5
scFv and Ki-4 scFv were selected on CD25- and CD30-positive
Hodgkin-derived L540Cy cells as published recently (27), and
their genes were released from phagemid vector pCANTAB6 by
SfiI/NotI digestion and inserted into
SfiI/NotI-restricted expression vector pBM1.1
containing an ETA' gene (31). The resulting plasmids were
transformed into E. coli BL21(DE3). For cloning of the
recombinant human CD30 receptor (rhCD30) gene fused to a poly-His tag
(20), cDNA of the extracellular part of CD30, including its
signal sequence (GenBank accession no. M83554 [12]),
was amplified by reverse transcription-PCR (30 cycles of 94°C for 1 min, 55°C for 2 min, and 72°C for 2 min) using proofreading Pfu DNA polymerase (Stratagene, La Jolla, Calif.) and the
oligonucleotide primers CD30-HisBack
(5'-g-cta-gag-cgg-ccg-ccc-acc-ATG-CGC-GTC-CTC-CTC-GCC-GCG-CTG-3' [the NotI consensus is underlined, and the CD30 coding
region is shown in capital letters]) and CD30-HisFor
(5'-gcc-gcg-ccc-tct-aga-tta-
-cgc-agc-tgc-CTT-CCC-CGT-GGA-GGA-GAG-AGC-GAC-3' [the XbaI consensus is underlined, the His6 tag
coding region is double underlined, and the CD30 coding region is shown
in capital letters]). The resulting PCR fragment was ligated into the
NotI/XbaI-linearized eukaryotic expression vector
pcDNA3 (Invitrogen) and transformed into E. coli XL1-Blue. A
60-µg portion of the sCD30-His-pcDNA3 plasmid was used for stable
transformation of 2 × 107 COS-1 cells using DOTAP
(Boehringer) according to the manufacturer's instructions. Transformed
COS cells were subcloned by limited dilutions in medium supplemented
with 2 mg of G418 (Boehringer)/ml.
Periplasmic expression and purification of the recombinant
immunotoxins.
Recombinant immunotoxins were expressed under the
control of the IPTG-inducible T7 lac promoter in E. coli BL21(DE3). Bacteria were grown overnight at 26°C in
Terrific Broth (TB) (35) containing 50 µg of kanamycin/ml
and 0.5 mM ZnCl2, since it has been shown earlier that
periplasmic proteolysis can be dramatically reduced upon addition of
this salt (2). The culture was diluted 30-fold in 200 ml of
the same medium. At an optical density at 600 nm (OD600) of
2, it was supplemented with 0.5 M sorbitol, 4% NaCl, and 10 mM glycine
betaine and was then incubated at 26°C for additional 30 to 60 min.
Thereafter, immunotoxin production was induced by the addition of 2 mM
IPTG at 26°C. Fifteen hours later, cells were harvested by
centrifugation at 3,700 × g for 10 min at 4°C. For
all the following steps, tubes were kept on ice. The bacterial pellet
was centrifuged, and its wet weight was determined. Cells were frozen
at
196°C. After thawing, the cells were resuspended in 75 mM
Tris-HCl (pH 8)-300 mM NaCl-1 capsule of protease inhibitors/50 ml
(Complete; Roche Diagnostics, Mannheim, Germany)-5 mM
dithiothreitol-10 mM EDTA-10% (vol/vol) glycerol and were sonicated
six times for 30 s at 200 W. The periplasmic fraction was
recovered after centrifugation at 21,000 × g for 30 min at 4°C and was transferred to 75 mM Tris-HCl (pH 8)-1 M
NaCl-10% (vol/vol) glycerol using Hitrap desalting columns
(Pharmacia). Recombinant immunotoxin was partially purified by
immobilized metal ion affinity chromatography (IMAC) with
nickel-nitriloacetic acid (Ni2+-NTA) chelating Sepharose
(Qiagen) on a BioLogic workstation (Bio-Rad, Munich, Germany). Bound
protein was eluted with 250 mM imidazole in 75 mM Tris-HCl (pH 8)-1 mM
NaCl-10% (vol/vol) glycerol. Fractions containing the RFT5 or Ki-4
scFv fused to the ETA' protein [RFT5(scFv)-ETA' or Ki-4(scFv)-ETA']
were pooled and concentrated by ultrafiltration. Because the
anticipated sizes of the recombinant immunotoxins were about 70 kDa,
they were finally purified using size exclusion chromatography with
Bio-Prep SE-100/17 columns (Bio-Rad) on a BioLogic workstation. Protein
was eluted with phosphate-buffered saline (PBS) (pH 7.4)-1 M NaCl,
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), and quantified by densitometry (GS-700 Imaging
Densitometer; Bio-Rad) after Coomassie staining in comparison with
bovine serum albumin (BSA) standards.
SDS-PAGE and Western blotting.
SDS-PAGE and Western blotting
were performed as described previously (4). GroEL was
detected by polyclonal anti-GroEL polyclonal rabbit antibodies (Sigma),
and immunotoxin was detected by the mouse anti-ETA' MAb TC-1 (kindly
provided by D. R. Galloway, Columbus, Ohio), combined with an
alkaline-phosphatase-conjugated sheep anti-rabbit immunoglobulin G
(IgG) MAb and an anti-mouse IgG MAb (Sigma), respectively.
Immunoprecipitation.
Extracts of identical wet weights of
bacteria cultured in TB or Luria-Bertani (LB) medium (35) at
26°C were prepared as described above. Particulate matter was removed
by centrifugation at 21,000 × g for 30 min. Clarified
soluble extracts were incubated with gentle shaking for 1 h at
4°C with 1 µg of rabbit polyclonal anti-GroEL (Sigma) antibody. The
samples were treated with 5 mg of swollen protein A-agarose (Sigma) and
mixed at 4°C for an additional hour. The immunoprecipitates were
washed, resuspended in 50 µl of reducing 2× SDS loading buffer
(Roth, Karlsruhe, Germany), and heated at 95°C for 5 min.
Supernatants were resolved on duplicate 10% SDS gels and transferred
to polyvinylidene difluoride membranes. GroEL and Ki-4(scFv)-ETA' were
visualized by incubation of the membranes with polyclonal anti-GroEL
and TC-1, respectively. Immunoblotting was performed as described above.
Binding assays.
Enzyme-linked immunosorbent assays (ELISA)
were performed as described previously (4) in 96-well
Maxisorb microtiter plates (Nunc, Wiesbaden, Germany) coated at 4°C
with 100 µl of either 125-ng/ml recombinant human interleukin-2
receptor-
(Biermann, Bad Nauheim, Germany) or rhCD30 in coating
buffer (0.2 M Na2CO3-0.2 M NaHCO3)
(Merck, Darmstadt, Germany)/well. Bound immunotoxin was detected with
the anti-ETA' MAb TC-1 and F(ab')2 fragments of
peroxidase-coupled goat anti-mouse IgG (Boehringer) (1:5,000 in
Tris-buffered saline containing 0.5% BSA and 0.05% Tween 20). Flow
cytometry was performed on cell suspensions containing 5 × 106 L540Cy cells/ml as described previously
(27). Bound immunotoxin was documented using MAb TC-1 and
fluorescein isothiocyanate (FITC)-labeled goat anti-mouse
immunoglobulin on a FACScan (Becton Dickinson, Heidelberg, Germany).
Binding specificity was verified by competition with excess parenteral
MAbs (10 µg/ml).
Colorimetric cell viability assay.
The metabolism of the
yellow tetrazolium salt XTT to a water-soluble orange formazan dye was
determined according to the manufacturer's instructions (Roche
Molecular Biochemicals, Mannheim, Germany). Various dilutions of the
recombinant toxins were distributed in 100-µl aliquots in 96-well
plates. Target cells (2 × 104 to 4 × 104) in 100-µl aliquots of complete medium were added,
and the plates were incubated for 48 h at 37°C. Afterwards, the
cell cultures were pulsed with 100 µl of fresh culture medium
supplemented with XTT and N-methyl dibenzopyrazine methyl
sulfate (PMS) (final concentrations, 1.49 and 0.025 mM, respectively)
for 4 h. The spectrophotometrical absorbances of the samples were
measured at 450 and 650 nm (reference wavelength) with an ELISA reader
(MWG Biotech, Ebersberg, Germany). The concentration required to
achieve a 50% reduction in cell viability relative to that of
untreated control cultures (50% inhibitory concentration
[IC50]) was calculated. All measurements were carried out
in triplicate.
Stress experiments.
Freeze-thawing experiments were
performed as described elsewhere (30). The residual
"after-stress" binding activities in at least three independent
ELISA experiments were determined, and the results were expressed as
percentages of "prestress" binding activities.
 |
RESULTS |
Construction of recombinant immunotoxins.
Recombinant
immunotoxins directed against the lymphoid activation markers CD25 and
CD30 for potential use in malignant lymphoma were developed. mRNAs were
isolated from the hybridoma cell lines RFT5 (anti-CD25) and Ki-4
(anti-CD30). After first-strand cDNA synthesis, PCR-amplified coding
regions of the light- and heavy-chain variable domains were assembled
to single-chain variable fragments, inserted into the phagemid vector
pCANTAB6, and expressed as minilibraries for display on filamentous
phage. Functional scFv's were obtained by selection of binding phage
on the Hodgkin lymphoma-derived CD25- and CD30-expressing cell line
L540Cy. The selected recombinant scFv's were shown to specifically
bind to their respective target antigens with binding kinetics similar
to those of the original antibodies (27). The selected
scFv's were inserted into the pET27b-derived expression vector pBM1.1
containing an IPTG-inducible lac operator, a pelB
signal peptide followed by a His10 tag, and ETA' (Fig.
1) (31). The deleted domain Ia
of Pseudomonas exotoxin responsible for nonspecific cell
recognition was thus replaced by the scFv's. The recombinant
immunotoxins constructed were designated RFT5(scFv)-ETA' and
Ki-4(scFv)-ETA', as described elsewhere (4, 27).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Cloning scheme of the bacterial expression vector
pBM1.1. The expression module (a) is composed of the signal peptide of
the pectate lyase gene (pelB), the IPTG-inducible T7
lac operon from the original pET vector (36), the
synthetic His10 cluster (His) (20), the
variable-region genes (VH and VL) connected by
(Gly4Ser)3 (linker), and the ETA' gene. Plasmid
pBM1.1 (b) contains the expression module, a kanamycin resistance gene
(Kanr), an E. coli origin of replication (pBR322
origin), an M13 origin of replication (f1 origin), and the lactose
repressor gene (lacI). The binding single-chain variable
fragments (scFv) are fused to ETA'.
|
|
Expression and purification.
Expression plasmids were
transformed into E. coli BL21(DE3). In a first series of
experiments, E. coli shaking cultures were grown to an
OD600 of 2.0 at salt concentrations of 4% NaCl plus 0.5 M
sorbitol, supplemented with 0, 2.5, 5, 10, or 20 mM glycine betaine.
Recombinant immunotoxins were directed to the periplasmic space after
induction with 2 mM IPTG, and the highest concentrations of
biologically active proteins were recovered in the presence of 10 mM
glycine betaine (data not shown). RFT5(scFv)- and Ki-4(scFv)-ETA' were
purified by a combination of IMAC and molecular size chromatography in
the presence of 10% glycerol. Recombinant immunotoxins were identified
by Western blotting and visualized with a MAb specific for correctly
folded Pseudomonas exotoxin A (17) (Fig.
2). Recently, it has been shown that
functionally active scorpion toxin Cn5 can be purified by means of
immobilized cytoplasmic and periplasmic chaperones such as GroEL,
disulfide isomerase, and peptidyl propyl cis-trans isomerase
(1). Thus, we compared our new method with a previously used
periplasmic expression protocol (26) by analysis of
polyclonal anti-GroEL-immunoprecipitated whole-cell protein fractions
(Fig. 3). The most striking difference is
documented by SDS-PAGE analysis: 2 h after induction of
immunotoxin expression, there is a dramatic increase in the levels of
precipitated proteins under osmotic stress conditions in the presence
of 10 mM glycine betaine (Fig. 3a, lane 6) compared to those under
standard growth conditions (Fig. 3a, lane 3). By Western blotting, full
length Ki-4(scFv)-ETA' was shown to be complexed in these chaperone
precipitates using the anti-ETA' MAb TC-1 (Fig. 3b). The presence of
GroEL was confirmed with the polyclonal anti-GroEL antibody described above (Fig. 3c). The amounts of TC-1-detectable fragmented protein were
two- and threefold higher under standard conditions than under osmotic
stress conditions without (data not shown) and with ZnCl2
(Fig. 3b, lanes 3 and 6), respectively. In addition, the ratio of
Ki-4(scFv)-ETA' to GroEL estimated by densitometric scanning was 0.45 under osmotic stress conditions and 1.3 under standard conditions. IMAC
was performed under high-salt conditions in order to prevent
nonspecific binding of the charged groups to the affinity matrix via an
ion-exchange effect (14). The recombinant immunotoxins were
substantially stabilized during purification by 1 M NaCl, eluted from
Ni2+-NTA columns by 250 mM imidazole, and afterwards
separated by size exclusion chromatography between 20 and 100 kDa (Fig.
4a). As can be seen in the elution
profile, only proteins smaller than 100 kDa, but no aggregates, were
collected. These data were also confirmed by nonreducing SDS-PAGE and
Western blotting; additionally, immunotoxin aggregates were not
detectable during protein preparation (Fig. 2b). Densitometry of
SDS-PAGE gels and Western blots as well as a receptor ELISA were used
to help establish the purity of the prepared proteins. The functional
immunotoxins, Ki-4(scFv)-ETA' and RFT5(scFv)-ETA', were enriched to
more than 95%. By exporting the immunotoxins to the periplasm of
E. coli, the final yield of functional protein varied around
1.1 mg/4.1 g of cell paste from bacterial shaking cultures (Table
2). In contrast to our former standard
periplasmic expression and extraction protocol, the functionality was
preserved after the extraction procedure. In addition, other ETA'-based
toxins fused to different binding structures (CD30 ligand
[5], interleukin-9 [26], three more anti-CD30 scFv's, and four additional scFv's targeting neuroblastoma, colon, and mammary carcinomas) were efficiently expressed by this new
method (data not shown).

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 2.
Purification of Ki-4(scFv)-ETA'. (a) 10% SDS-PAGE gel
at different steps of purification. Lanes: M, molecular mass markers
(with values in kilodaltons shown on the left); 1, soluble periplasmic
content; 2, IMAC flowthrough; 3, IMAC eluate eluted with 250 mM
imidazole; 4, Ki-4(scFv)-ETA' after size exclusion chromatography. The
gel was stained with Coomassie brilliant blue. (b) Corresponding
Western blot. The recombinant immunotoxin was detected using the
anti-ETA' MAb TC-1 combined with alkaline-phosphatase-conjugated
anti-mouse IgG MAbs and fast red. Arrowheads indicate the positions of
Ki-4(scFv)-ETA'.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 3.
Comparative analyses of polyclonal anti-GroEL
immunoprecipitates. (a) 10% SDS-PAGE of precipitated proteins; (b and
c) Western blot analyses of Ki-4(scFv)-ETA' and GroEL, respectively.
Results are shown for standard growth conditions (LB medium with 150 mM
NaCl) (lanes 1 through 3) and osmotic-stress growth conditions in the
presence of 10 mM glycine betaine (lanes 4 through 6). Lanes 1 and 4, before stress and IPTG induction; lane 2, 1/2 h before IPTG induction;
lane 5, 1/2 h after supplementation with NaCl, sorbitol, and glycine
betaine; lanes 3 and 6, 2 h after IPTG induction. Arrowhead
indicates the position of Ki-4(scFv)-ETA'.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
Functional activity of purified recombinant immunotoxins
after size exclusion chromatography using Bio-Prep SE-100/17 columns.
(a) Elution profile monitored at 280 nm (solid line) combined with
binding activity of the eluted fractions as documented by ELISA (dashed
line). Immobilized rhCD30 receptor was incubated with dilutions of
fractions from the column. Specifically bound Ki-4(scFv)-ETA' was
detected after incubation with the anti-ETA' MAb TC-1 followed by
alkaline-phosphatase-conjugated anti-mouse IgG. Converted substrate
(o-phenylenediamine-dihydrochloride) was measured as
absorbance at 405 nm. (b) Cell-binding activities of RFT5(scFv)- and
Ki-4(scFv)-ETA' as evaluated by flow cytometry analysis. (i)
CD25+ CD30+ Hodgkin-derived L540Cy cells were
incubated with PBS (open), and CD25 CD30
Hodgkin-derived HD-MyZ cells (shaded) or L540Cy cells (solid) were
incubated with RFT5(scFv)-ETA', for 15 min at 4°C. (ii) L540Cy cells
were incubated with PBS (open), and HD-MyZ (shaded) or L540Cy (solid)
were incubated with Ki-4(scFv)-ETA', for 15 min at 4°C. Cells were
stained with TC-1, mouse anti-TC-1, and goat anti-mouse FITC-conjugated
antibody. Immunofluorescence (FL1 channel) was measured by flow
cytometry, using a FACScan.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Recovery of Ki-4(scFv)-ETA' from E. coli
BL21(DE3) cultured under osmotic-stress conditions in the presence of
10 mM glycine betaine
|
|
Functionality.
The binding properties of the recombinant
proteins against the CD25 and CD30 antigens were demonstrated by ELISA
analyses using MAb TC-1 (Fig. 4a). The recombinant immunotoxins bound
to their respective recombinant human target antigens. Additionally, binding of the final preparation was also documented by flow cytometry as shown for Ki-4(scFv)-ETA' and RFT5(scFv)-ETA'. The recombinant proteins bound to the CD25+ CD30+ cell line
L540Cy but not to the antigen-negative cell line HD-MyZ (Fig. 4b).
Antigen specificity was documented by competitive ELISA experiments.
The binding of RFT5(scFv)-ETA' and Ki-4(scFv)-ETA' against both CD25 or
CD30 antigen-positive cell membrane fractions and recombinant CD25 or
rhCD30 receptor was inhibited by 10 µg of soluble CD25 receptor (Fig.
5a, inset) or MAb Ki-4 (data not shown)/ml, respectively.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 5.
Growth inhibition of Hodgkin-derived cell lines after
incubation with recombinant immunotoxins as documented by cell
viability assays. L540Cy (CD25+ CD30+) and
HD-MyZ (CD25 CD30 ) cells were treated with
the immunotoxins, and their abilities to metabolize the tetrazolium
salt XTT to a water-soluble formazan salt (formed by mitochondrial
dehydrogenase activity) were measured as absorbance at 450 and 650 nm
(reference wavelength) in a cell viability assay (24). (a)
Cytotoxic activities of 1:10 dilutions of RFT5(scFv)-ETA' on L540Cy
cells. (Inset) RFT5(scFv)-ETA' (10 µg/ml in PBS) showed 100% binding
activity on immobilized CD25 receptor; binding was reduced to <15%
after the addition of 10 µg of soluble CD25 rCD25R receptor/ml. (b)
Cytotoxic activity of Ki-4(scFv)-ETA' on L540Cy cells (competition with
MAb Ki-4).
|
|
To characterize the cytotoxic activity of the recombinant immunotoxins
in vitro, we measured their ability to reduce the viability
of target
cells (Fig.
5). Both Ki-4(scFv)-ETA' and RFT5(scFv)-ETA'
were
specifically cytotoxic to L540Cy cells, with calculated
IC
50s
of 6 and 12 ng/ml, respectively. The
CD30

CD25

cell line HD-MyZ was not affected
at recombinant protein concentrations
up to 10 µg/ml. Again, antigen
specificity was documented by competition
with 10 µg of MAb Ki-4
(Fig.
5b) or RFT5 (data not shown)/ml in
cell viability
assays.
Stability.
To analyze possible effects of self-stabilization,
increasing protein concentrations were tested for residual binding
activity after one freeze-thawing step (data not shown). Experiments
with the unmodified parental Ki-4 MAb and recombinant immunotoxin
Ki-4(scFv)-ETA' confirmed that increasing protein concentrations are
correlated with enhanced resistance against fast freezing and slow
thawing. Immunotoxins were much more sensitive in these experiments
than MAbs. Based on these results, subsequent experiments were
performed at protein concentrations of 1 µg/ml.
The binding activities of MAb Ki-4 and recombinant immunotoxin with
respect to the frequency of freezing and thawing are depicted
in Fig.
6a. Repeated freezing and thawing was
correlated with
losses of as much as 30% of the binding activity for
MAb Ki-4
and 99% for the immunotoxin.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 6.
Cryoprotection and stabilization of 1 µg of
CD30-binding proteins/ml by compatible solutes were measured as
relative binding activity by a CD30 receptor ELISA. Specifically bound
Ki-4(scFv)-ETA' was detected after incubation with the anti-ETA' MAb
TC-1 followed by alkaline-phosphatase-conjugated anti-mouse IgG, and
bound MAb Ki-4 was detected by alkaline-phosphatase-conjugated
anti-mouse IgG. Converted phosphatase substrate
(o-phenylenediamine-dihydrochloride) was measured as
absorbance at 405 nm. (a) Relative binding activity of Ki-4(scFv)-ETA'
(open bars) compared to that of MAb Ki-4 (solid bars) after several
rounds of freeze-thawing. (b) Relative binding activities of
Ki-4(scFv)-ETA' (open bars) and MAb Ki-4 (solid bars) in the presence
of 1 M hydroxyectoine.
|
|
In order to assess the efficiency of compatible solutes as stabilizers
of binding structures and enzymes (
30), the freeze-thaw
experiments were repeated in the presence of 1 M hydroxyectoine.
Generally, supplementation with compatible solutes resulted in
significantly higher activity of the proteins investigated. Using
hydroxyectoine, the stabilizing properties ranged between 100
and 89%
for MAb Ki-4 after one to four cycles of freezing and
thawing (Fig.
6b). For Ki-4(scFv)-ETA', the most obvious protection
(100%) was
achieved after one cycle of freeze-thawing compared
to 16% without
compatible solutes; after four cycles in the presence
of hydroxyectoine
the residual binding activity was 89%, compared
to 0% without
hydroxyectoine. Control experiments with 1 M NaCl
or 10% glycerin
resulted in 50%-reduced stability in contrast
to experiments with
hydroxyectoine (data not
shown).
Hydroxyectoine-stabilized Ki-4(scFv)-ETA' which had undergone four
cycles of freeze-thawing (ca. 90% residual binding activity)
was
tested for its cytotoxic activity against L540Cy cells. The
IC
50 was slightly reduced (7 ng/ml) compared to that for
unfrozen
protein; 10 mM hydroxyectoine alone and identically treated
Ki-4(scFv)-ETA'
probes without protectants had no influence on cell
viability
(data not
shown).
 |
DISCUSSION |
In this study, we report the development of a new protocol for
periplasmic expression of recombinant proteins. The major findings emerging from our study are as follows. (i) Both recombinant
immunotoxins examined were directionally expressed into the periplasmic
space of E. coli BL21(DE3) and functionally purified by a
combination of metal ion affinity and molecular size chromatography.
(ii) Functional protein in sufficient amounts was generated only under osmotic stress (high-salt, low-water) conditions in the presence of
compatible solutes. (iii) The protein-stabilizing functions of the
compatible solutes were documented under storage conditions in PBS by
freeze-thawing experiments at low protein concentrations.
The standard method used hitherto to purify Pseudomonas
exotoxin-based recombinant proteins is to accumulate these proteins in
inclusion bodies by coprecipitation in a denatured state together with
ribosomes, nucleic acids, or other cytoplasmic proteins. The proteins
are then recovered by de- and renaturation as originally described by
Buchner et al. (9). A combination of factors relating to the
physiological state of the cell and the growth conditions determine the
formation of inclusion bodies. The reducing environment in the
cytoplasm prevents the formation of disulfide bonds. Thus, proteins
requiring disulfide bonds to assume their native conformation should be
directed into the nonreducing periplasmic compartment of E. coli (37).
The use of compatible solutes as a means to counteract the insolubility
of recombinant proteins has been described for recombinant ferritin. In
these experiments, expression at 25°C in the presence of sorbitol and
glycine betaine gave perfectly assembled and functional cytoplasmic
protein (38). Similarly, E. coli transformed with the high-level expression vector pMON5525 formed insoluble complexes of
recombinant dimethylallyl pyrophosphatase-AMP transferase at 27°C
(7). When the same experiment was performed under osmotic stress (170 mM NaCl) in the presence of 1 M sorbitol and glycine betaine (2.5 mM), large amounts of active, soluble cytoplasmic protein
were obtained. The use of compatible-solute-assisted stress conditions
in our hands resulted in unprecedented yields of functional recombinant
immunotoxins. At 4% NaCl, 0.5 M sorbitol, and 10 mM glycine betaine,
more than 95% functional protein was accumulated in the periplasm in
contrast to less than 10% under standard conditions. Importantly,
neither aggregation products nor unprocessed proteins were detectable.
The underlying principle of hyperosmotic-stress-governed and
solute-assisted expression is poorly understood. Combined effects are
thought to influence productivity in the following ways: (i) by
induction of heat shock proteins by stress, (ii) by establishing a
stabilizing microenvironment in the periplasm by high salt
concentrations, (iii) by enabling bacterial growth under the described
osmotic-stress conditions in the presence of compatible solutes, and
(iv) by direct interaction of compatible solutes with recombinant
proteins after active uptake via proP and proU at high osmolarity. It
is known, however, that under the conditions used (4% NaCl plus 0.5 M
sorbitol, equivalent to an osmolarity of approximately 2 osM), glycine
betaine and hydroxyectoine are efficiently taken up by E. coli via the proP and proU transport systems (10). One
would therefore expect a concentration of at least 500 mM compatible solutes in the cells and subsequent modification of the cytosolic environment of the expression system. This salt stress situation alone,
in combination with a considerably reduced metabolic rate, may be
sufficient to explain the observed effect on the folding of recombinant
proteins. However, one should keep in mind that moderate salt stress as
applied in our experiments would have far-reaching effects on cellular
metabolism. As has been pointed out by Hengge-Aronis (19)
and others, the addition of salt and/or sucrose increases the
intracellular level of sigma factor S and, as a consequence, induces a
whole range of stress response mechanisms, including thermotolerance
and starvation survival. It may therefore well be possible that
additional elements of protein protection include the induction of
chaperones and/or indirect effects on the presence and activity of
periplasmic proteolytic enzymes during cultivation. In fact, our
immunoprecipitation experiments documented a Ki-4(scFv)-ETA'/GroEL
ratio of 0.45 and reduced proteolysis resulting in higher yields of
functional immunotoxins by optimized concentrations of
immunotoxin-bound chaperones under low-water conditions. This is in
accordance with the data of Phillips and Silhavy, who demonstrated that
the cytoplasmic solubility and/or secretion of a number of
aggregation-prone heterologues can be improved by the
overproduction of components of either the DanK-DnaJ-GrpE or the
GroEL-GroES chaperone complex (34).
The results presented in this paper show that the compatible solutes
tested, including glycine betaine and hydroxyectoine, efficiently
protected recombinant fusion proteins against degradation, aggregation,
misfolding, and freezing. Our data are supported by findings of Lippert
and Galinski (30), who compared the effects of
freeze-thawing, heating, and freeze-drying on the enzymatic activities
of lactic dehydrogenase and phosphofructokinase. The enzymes tested
were highly sensitive to each of these three destabilizing factors but
retained more than 90% of their activities when stabilized with
hydroxyectoine after four cycles of freeze-thawing. The prime importance of glycine betaine and hydroxyectoine as protein protectants has recently been emphasized (18, 28).
Compatible-solute-supported periplasmic expression may offer an
attractive new tool for the high-yield production of functional and
stable recombinant proteins. In addition, the major principles of the
new method described in this paper, i.e., high-salt-low-water conditions and supplementation with compatible solutes, might also be
generally applicable to other expression systems.
 |
ACKNOWLEDGMENTS |
We thank Darrell R. Galloway for providing the monoclonal
anti-ETA' hybridoma TC-1. We also thank Silke Drillich for cloning assistance and Gisela Schön for performing the toxicity assays.
This work was supported in part by the Deutsche Forschungsgemeinschaft,
grants SFB502 and TFB 6-98.
S.B. and M.H. contributed equally to this work.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Medizinische
Klinik I der Universität zu Köln, Labor für
Immuntherapie, Joseph-Stelzmann-Str. 9, D-50931 Köln, Germany.
Phone: 49 (0) 221 478-3593. Fax: 49 (0) 221 478-6383. E-mail:
stefan.barth{at}uni-koeln.de.
 |
REFERENCES |
| 1.
|
Altamiro, M. M.,
C. Garcia,
L. D. Possani, and A. R. Fersht.
1999.
Oxidative refolding chromatography: folding of the scorpion toxin Cn5.
Nat. Biotechnol.
17:187-191[CrossRef][Medline].
|
| 2.
|
Baneyx, F., and G. Georgiou.
1992.
Degradation of secreted proteins in Escherichia coli.
Ann. N. Y. Acad. Sci.
665:301-308[Medline].
|
| 3.
|
Bargou, R. C.,
M. Y. Mapara,
C. Zugck,
P. T. Daniel,
M. Pawlita,
H. Dohner, and B. Dorken.
1993.
Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice.
J. Exp. Med.
177:1257-1268[Abstract/Free Full Text].
|
| 4.
|
Barth, S.,
M. Huhn,
W. Wels,
V. Diehl, and A. Engert.
1998.
Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
Int. J. Mol. Med.
1:249-256[Medline].
|
| 5.
|
Barth, S.,
B. Matthey,
M. Huhn,
V. Diehl, and A. Engert.
1999.
CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.
Cytokines Cell. Mol. Ther.
5:69-78[Medline].
|
| 6.
|
Benhar, I., and I. Pastan.
1994.
Cloning, expression and characterization of the Fv fragments of the anti-carbohydrate mAbs B1 and B5 as single-chain immunotoxins.
Protein Eng.
7:1509-1515[Abstract/Free Full Text].
|
| 7.
|
Blackwell, J. R., and R. Horgan.
1991.
A novel strategy for production of a highly expressed recombinant protein in an active form.
FEBS Lett.
295:10-12[CrossRef][Medline].
|
| 8.
|
Brown, A. D.
1976.
Microbial water stress.
Bacteriol. Rev.
40:803-846[Free Full Text].
|
| 9.
|
Buchner, J.,
I. Pastan, and U. Brinkmann.
1992.
A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies.
Anal. Biochem.
205:263-270[CrossRef][Medline].
|
| 10.
|
Csonka, L., and W. Epstein.
1996.
Osmoregulation, p. 1210-1223.
In
F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), Escherichia coli and Salmonella: cellular and molecular biology, 2nd ed., vol. 1. ASM Press, Washington, D.C.
|
| 11.
|
Dower, W. J.,
J. F. Miller, and C. W. Ragsdale.
1988.
High efficiency transformation of E. coli by high voltage electroporation.
Nucleic Acids Res.
16:6127-6145[Abstract/Free Full Text].
|
| 12.
|
Durkop, H.,
U. Latza,
M. Hummel,
F. Eitelbach,
B. Seed, and H. Stein.
1992.
Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease.
Cell
68:421-427[CrossRef][Medline].
|
| 13.
|
Engert, A.,
G. Martin,
P. Amlot,
J. Wijdenes,
V. Diehl, and P. Thorpe.
1991.
Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice.
Int. J. Cancer
49:450-456[Medline].
|
| 14.
|
Essen, L., and A. Skerra.
1993.
Single-step purification of a bacterially expressed antibody Fv fragment by immobilized metal affinity chromatography in the presence of betaine.
J. Chromatogr. A
657:55-61[CrossRef][Medline].
|
| 15.
|
FitzGerald, D.,
I. Pastan, and J. Robertus.
1998.
Clinical applications of immunotoxins. Introduction.
Curr. Top. Microbiol. Immunol.
234:1-11[Medline].
|
| 16.
|
Galinski, E.
1995.
Osmoadaptation in bacteria.
Adv. Microb. Physiol.
37:272-328[Medline].
|
| 17.
|
Galloway, D. R.,
R. C. Hedstrom, and O. R. Pavlovskis.
1984.
Production and characterization of monoclonal antibodies to exotoxin A from Pseudomonas aeruginosa.
Infect. Immun.
44:262-267[Abstract/Free Full Text].
|
| 18.
|
Göller, K., and E. A. Galinski.
1999.
Protection of a model enzyme (lactate dehydrogenase) against heat, urea and freeze-thaw treatment by compatible solute additives.
J. Mol. Catal. B Enzymatic
7:37-45.
|
| 19.
|
Hengge-Aronis, R.
1996.
Back to log phase: sigma S as a global regulator in the osmotic control of gene expression in Escherichia coli.
Mol. Microbiol.
21:887-893[CrossRef][Medline].
|
| 20.
|
Hochuli, E.,
H. Dobeli, and A. Schacher.
1987.
New metal chelate adsorbent selective for proteins and peptides containing neighbouring histidine residues.
J. Chromatogr.
411:177-184[CrossRef][Medline].
|
| 21.
|
Holliger, P., and G. Winter.
1997.
Diabodies: small bispecific antibody fragments.
Cancer Immunol. Immunother.
45:128-130[CrossRef][Medline].
|
| 22.
|
Hoogenboom, H. R.,
J. D. Marks,
A. D. Griffiths, and G. Winter.
1992.
Building antibodies from their genes.
Immunol. Rev.
130:41-68[CrossRef][Medline].
|
| 23.
|
Horn-Lohrens, O.,
M. Tiemann,
H. Lange,
J. Kobarg,
M. Hafner,
H. Hansen,
W. Sterry,
R. Parwaresch, and H. Lemke.
1995.
Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4).
Int. J. Cancer
60:539-544[Medline].
|
| 24.
|
Jost, L. M.,
J. M. Kirkwood, and T. L. Whiteside.
1992.
Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells.
J. Immunol. Methods
147:153-165[Medline].
|
| 25.
|
Kapp, U.,
J. Wolf,
C. von Kalle,
S. Tawadros,
A. Rottgen,
A. Engert,
C. Fonatsch,
H. Stein, and V. Diehl.
1992.
Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice.
Ann. Oncol.
3(Suppl. 4):21-23.
|
| 26.
|
Klimka, A.,
S. Barth,
S. Drillich,
W. Wels,
J. van Snick,
J. C. Renauld,
H. Tesch,
H. Bohlen,
V. Diehl, and A. Engert.
1996.
A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines.
Cytokines Mol. Ther.
2:139-146[Medline].
|
| 27.
|
Klimka, A.,
S. Barth,
B. Matthey,
R. C. Roovers,
H. Lemke,
H. Hansen,
J. W. Arends,
V. Diehl,
H. R. Hoogenboom, and A. Engert.
1999.
An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
Br. J. Cancer
80:1214-1222[CrossRef][Medline].
|
| 28.
|
Knapp, S.,
R. Ladenstein, and E. A. Galinski.
1999.
Thermal stabilisation of bovine ribonuclease A by the naturally occurring osmolytes beta-hydroxyectoine and betaine.
Extremophiles
3:191-198[CrossRef][Medline].
|
| 29.
|
Kreitman, R., and I. Pastan.
1994.
Recombinant toxins.
Adv. Pharmacol.
28:193-219.
|
| 30.
|
Lippert, K., and E. A. Galinski.
1992.
Enzyme stabilization by ectoine-type compatible solutes: protection against heating, freezing and drying.
Appl. Microbiol. Biotechnol.
37:61-65.
|
| 31.
|
Matthey, B.,
A. Engert,
A. Klimka,
V. Diehl, and S. Barth.
1999.
A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins.
Gene
229:145-153[CrossRef][Medline].
|
| 32.
|
McCafferty, J.,
K. J. Fitzgerald,
J. Earnshaw,
D. J. Chiswell,
J. Link,
R. Smith, and J. Kenten.
1994.
Selection and rapid purification of murine antibody fragments that bind a transition-state analog by phage display.
Appl. Biochem. Biotechnol.
47:157-171[Medline].
|
| 33.
|
Pastan, I., and D. FitzGerald.
1991.
Recombinant toxins for cancer treatment.
Science
254:1173-1177[Abstract/Free Full Text].
|
| 34.
|
Phillips, G., and T. Silhavy.
1990.
Heat-shock proteins DnaK and GroEL facilitate export of LacZ hybrid proteins in E. coli.
Nature
344:882-884[CrossRef][Medline].
|
| 35.
|
Sambrook, J.,
E. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 36.
|
Studier, F. W., and B. A. Moffatt.
1986.
Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes.
J. Mol. Biol.
189:113-130[CrossRef][Medline].
|
| 37.
|
Talmadge, K., and W. Gilbert.
1982.
Cellular location affects protein stability in Escherichia coli.
Proc. Natl. Acad. Sci. USA
79:1830-1833[Abstract/Free Full Text].
|
| 38.
|
Van Wuytswinkel, O.,
G. Savino, and J. Briat.
1995.
Purification and characterization of recombinant pea-seed ferritins expressed in Escherichia coli: influence of N-terminus deletions on protein solubility and core formation in vitro.
Biochem. J.
305:253-261.
|
| 39.
|
Wels, W.,
I. Harwerth,
M. Mueller,
B. Groner, and N. Hynes.
1992.
Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor.
Cancer Res.
52:6310-6317[Abstract/Free Full Text].
|
Applied and Environmental Microbiology, April 2000, p. 1572-1579, Vol. 66, No. 4
0099-2240/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Bursy, J., Kuhlmann, A. U., Pittelkow, M., Hartmann, H., Jebbar, M., Pierik, A. J., Bremer, E.
(2008). Synthesis and Uptake of the Compatible Solutes Ectoine and 5-Hydroxyectoine by Streptomyces coelicolor A3(2) in Response to Salt and Heat Stresses. Appl. Environ. Microbiol.
74: 7286-7296
[Abstract]
[Full Text]
-
Menzel, C., Schirrmann, T., Konthur, Z., Jostock, T., Dubel, S.
(2008). Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood
111: 3830-3837
[Abstract]
[Full Text]
-
Sosio, M., Kloosterman, H., Bianchi, A., de Vreugd, P., Dijkhuizen, L., Donadio, S.
(2004). Organization of the teicoplanin gene cluster in Actinoplanes teichomyceticus. Microbiology
150: 95-102
[Abstract]
[Full Text]
-
Tur, M. K., Huhn, M., Thepen, T., Stocker, M., Krohn, R., Vogel, S., Jost, E., Osieka, R., van de Winkel, J. G., Fischer, R., Finnern, R., Barth, S.
(2003). Recombinant CD64-Specific Single Chain Immunotoxin Exhibits Specific Cytotoxicity against Acute Myeloid Leukemia Cells. Cancer Res.
63: 8414-8419
[Abstract]
[Full Text]
-
Ackerley, D. F., Caradoc-Davies, T. T., Lamont, I. L.
(2003). Substrate Specificity of the Nonribosomal Peptide Synthetase PvdD from Pseudomonas aeruginosa. J. Bacteriol.
185: 2848-2855
[Abstract]
[Full Text]
-
Huhn, M., Sasse, S., Tur, M. K., Matthey, B., Schinkothe, T., Rybak, S. M., Barth, S., Engert, A.
(2001). Human Angiogenin Fused to Human CD30 Ligand (Ang-CD30L) Exhibits Specific Cytotoxicity against CD30-positive Lymphoma. Cancer Res.
61: 8737-8742
[Abstract]
[Full Text]
-
Barth, S., Huhn, M., Matthey, B., Tawadros, S., Schnell, R., Schinkothe, T., Diehl, V., Engert, A.
(2000). Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood
95: 3909-3914
[Abstract]
[Full Text]